Press Release

Corsair Pharma Announces Three Presentations of Phase 1 Clinical Data for TRX-248 Transdermal System at the 2026 Pulmonary Hypertension Association Conference

Corsair Pharma Announces Positive Phase 1 Results for the TRX-248 Transdermal System in Pulmonary Arterial Hypertension

Corsair Pharma to Present New Data on Proprietary Treprostinil Prodrug Transdermal System at PHPN 2025 Symposium

Corsair Pharma Announces Successful Completion of Preclinical Program for Its Treprostinil Prodrug Transdermal System

Corsair Pharma Announces Appointment of George W. Mahaffey as Chief Executive Officer

Corsair Pharma Announces $23 Million Series B Financing to Advance Clinical Trials in PAH